| El Proyecto Del Barrio Center For A Healthy Community | |
|
20800 Sherman Way Winnetka CA 91306-2707 | |
| (818) 883-2273 | |
| (818) 347-4257 |
| Full Name | El Proyecto Del Barrio Center For A Healthy Community |
|---|---|
| Speciality | Clinic/Center |
| Location | 20800 Sherman Way, Winnetka, California |
| Authorized Official Name and Position | Corinne Sanchez (PRESIDENT CEO) |
| Authorized Official Contact | 8188307133 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| El Proyecto Del Barrio Center For A Healthy Community 20800 Sherman Way Winnetka CA 91306-2707 Ph: (818) 883-2273 | El Proyecto Del Barrio Center For A Healthy Community 20800 Sherman Way Winnetka CA 91306-2707 Ph: (818) 883-2273 |
| NPI Number | 1538130893 |
|---|---|
| Provider Enumeration Date | 01/26/2006 |
| Last Update Date | 07/01/2008 |
| Medicare PECOS PAC ID | 3476546227 |
|---|---|
| Medicare Enrollment ID | O20070817000727 |
News Archive
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
After a doctor at Adelaide's Women's and Children's Hospital tested positive for tuberculosis (TB), authorities say as many as 300 babies have been identified who may have come into contact with the doctor and could be at risk.
KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).
IVAX Corporation announced today a revised offer to acquire the shares of Kutnowskie Zaklady Farmaceutyczne Polfa SA ("Polfa Kutno"). IVAX intends to acquire, in exchange for IVAX stock, up to 100%, but not less than 75% of the shares of Polfa Kutno for a price of 340 PLN per share.
Cancer and many other diseases are based on genetic defects. The body can often compensate for the defect of one gene; it is only the combination of several genetic errors that leads to the clinical picture.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538130893 | NPI | - | NPPES |
| HAP70769F | Other | CA | FAM PLANNING |
| FHC70769F | Medicaid | CA | |
| BCP70769F | Other | CA | BREAST/CERVICAL CANCER PR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | (* (Not Available)) | Primary |
News Archive
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
After a doctor at Adelaide's Women's and Children's Hospital tested positive for tuberculosis (TB), authorities say as many as 300 babies have been identified who may have come into contact with the doctor and could be at risk.
KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).
IVAX Corporation announced today a revised offer to acquire the shares of Kutnowskie Zaklady Farmaceutyczne Polfa SA ("Polfa Kutno"). IVAX intends to acquire, in exchange for IVAX stock, up to 100%, but not less than 75% of the shares of Polfa Kutno for a price of 340 PLN per share.
Cancer and many other diseases are based on genetic defects. The body can often compensate for the defect of one gene; it is only the combination of several genetic errors that leads to the clinical picture.
› Verified 9 days ago
Shauna Collins, Md Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7657 Winnetka Ave, Suite 344, Winnetka, CA 91306 Phone: 818-585-2381 | |
Etehad M.d., Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7667 Winnetka Ave, Winnetka, CA 91306 Phone: 818-812-9466 | |
Health & Beauty Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 6742 Winnetka Ave, Winnetka, CA 91306 Phone: 818-888-4063 Fax: 818-888-4064 | |
Endeavor Medical Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 20246 Saticoy St Ste 201, Winnetka, CA 91306 Phone: 818-812-9506 Fax: 818-812-9508 |